December 15th, 2015

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Adaptimmune Ther Ads (NQ: ADAP )

5.800 USD -0.300 (-4.92%)
Streaming Delayed Price Updated: 3:28 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Adaptimmune Ther Ads

< Previous 1 2 3 4 5 6 7 Next >
Adaptimmune Reports Second Quarter 2017 Financial Results
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results and business updates for the quarter ended June 30, 2017. 
From GlobeNewswire News Releases
Adaptimmune to Report Second Quarter 2017 Financial Results on August 3, 2017
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer will announce financial results for the quarter ended June 30, 2017 before the open of the U.S. markets on... 
From GlobeNewswire News Releases
Adaptimmune Announces an Oral Presentation on Data from NY-ESO Study in Synovial Sarcoma and Four Trials in Progress Posters at the American Society of Clinical Oncology (ASCO) Annual Meeting
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced an oral presentation on updated data from its NY-ESO study in synovial sarcoma, as well as four... 
From GlobeNewswire News Releases
Adaptimmune Announces an Oral Presentation and Four Trials in Progress Posters at the American Society of Clinical Oncology (ASCO) Annual Meeting
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced an oral presentation, as well as four trials in progress posters, at the 2017 ASCO annual meeting... 
From GlobeNewswire News Releases
Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting NY-ESO in Combination with KEYTRUDA® (pembrolizumab) in Multiple Myeloma
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated its study of NY-ESO SPEAR T?cells targeting NY-ESO in combination with... 
From GlobeNewswire News Releases
Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated the first site for its MAGE?A4 SPEAR T-cell study in patients with multiple... 
From GlobeNewswire News Releases
Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting AFP in Liver Cancer
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated the first site for its AFP SPEAR T-cell study in patients with locally... 
From GlobeNewswire News Releases
Adaptimmune Reports First Quarter 2017 Financial Results
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results and business updates for the quarter ended March 31, 2017. 
From GlobeNewswire News Releases
Adaptimmune to Report First Quarter 2017 Financial Results on May 10, 2017
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the quarter ended March 31, 2017 before the open of the U.S. markets on... 
From GlobeNewswire News Releases
Adaptimmune to Present at Upcoming Deutsche Bank 42nd Annual Health Care Conference
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Adaptimmune’s Chief Executive Officer, will be presenting at the Deutsche Bank... 
From GlobeNewswire News Releases
Adaptimmune Therapeutics plc Announces Closing of $42 Million Registered Direct Offering
Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced registered direct offering of its... 
From GlobeNewswire News Releases
Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares
Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a definitive agreement with Matrix Capital Management... 
From GlobeNewswire News Releases
Adaptimmune to Participate in Upcoming Jefferies Immuno-Oncology Summit
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Adaptimmune’s Chief Executive Officer, and Gwen Binder-Scholl, Adaptimmune’s... 
From GlobeNewswire News Releases
Adaptimmune Therapeutics plc Announces Closing of Public Offering and Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced underwritten public offering of its... 
From GlobeNewswire News Releases
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares
Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 14,300,000 of its American... 
From GlobeNewswire News Releases
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it intends to offer and sell American Depositary Shares (“ADSs”) in an underwritten public... 
From GlobeNewswire News Releases
Adaptimmune Broadens Executive Team
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has broadened its executive team with the appointment of co-founder, Helen Tayton-Martin,... 
From GlobeNewswire News Releases
Adaptimmune Reports Fourth Quarter and Full Year 2016 Financial Results
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2016. 
From GlobeNewswire News Releases
Adaptimmune to Report Fourth Quarter and Full Year 2016 Financial Results on March 13, 2017
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the fourth quarter and full year ended December 31, 2016 before the open of... 
From GlobeNewswire News Releases
Adaptimmune to Present at the Cowen and Company 37th Annual Health Care Conference
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Adaptimmune’s Chief Executive Officer, will present at the Cowen and Company... 
From GlobeNewswire News Releases
Adaptimmune Cuts Ribbon on U.S. Headquarters at the Navy Yard in Philadelphia
Company Officially Opens Doors to New Base for Clinical and Manufacturing Operations 
From GlobeNewswire News Releases
Adaptimmune to Participate in Upcoming Investor Conference
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Adrian Rawcliffe, Adaptimmune’s Chief Financial Officer, will present at the Leerink 6th... 
From GlobeNewswire News Releases
Adaptimmune confirms GSK Nomination of Second Adaptimmune Target under Strategic Multi-Target Collaboration
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that GlaxoSmithKline plc (NYSE:GSK) (LSE:GSK) has nominated a second target, PRAME... 
From GlobeNewswire News Releases
Adaptimmune Announces New Senior Vice President of Global Bio-Process and Development
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Mark E. Dudley, Ph.D. has joined the company as Senior Vice President of Global Bio-Process... 
From GlobeNewswire News Releases
Adaptimmune Announces FDA Acceptance of IND Application for Affinity Enhanced T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the US Food and Drug Administration (FDA) has accepted the Company’s investigational new... 
From GlobeNewswire News Releases
Adaptimmune and Bellicum Pharmaceuticals Enter a Strategic Collaboration to Evaluate Next-Generation T-Cell Therapies
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular... 
From GlobeNewswire News Releases
Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma Study
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated a study of its NY?ESO SPEAR™ T?cells in myxoid/round cell liposarcoma... 
From GlobeNewswire News Releases
Adaptimmune Announces Update on Clinical Data from NY-ESO SPEAR™ T-cell Synovial Sarcoma Study at the 2016 Annual Meeting of the Connective Tissue Oncology Society (CTOS)
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced an oral presentation with updated data on its study of NY?ESO SPEAR™ (Specific Peptide Enhanced... 
From GlobeNewswire News Releases
Adaptimmune Presents Preclinical Data from a New, Wholly-owned SPEAR™ T-cell and a Second Generation SPEAR T-cell at the 31st Annual Meeting of the Society for Immunotherapy for Cancer (SITC)
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the presentation of data at the 2016 Society for Immunotherapy for Cancer (SITC) annual meeting.... 
From GlobeNewswire News Releases
Adaptimmune Reports Third Quarter 2016 Financial Results
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results for the third quarter ended September 30, 2016. 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

3257 Dunmore Rd SE
Medicine Hat, AB T1B 3R2

[P] 403.527.1101
[F] 403.528.5696

Print Advertising: 403.528.5650
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2015 The Medicine Hat News, A Division of Continental Newspapers Canada Ltd.